Table

Serologic Prevalence of Ebola Virus in Equatorial Africa

Imke Steffen¹, Kai Lu, Lauren K. Yamamoto, Nicole A. Hoff, Prime Mulembakani, Emile O. Wemakoy, Jean-Jacques Muyembe-Tamfum, Nicaise Ndembi, Catherine A. Brennan, John Hackett, Susan L. Stramer, William M. Switzer, Sentob Saragosti, Guy O. Mbensa, Syria Laperche, Anne W. Rimoin, and Graham Simmons

Author affiliations: Vitalant Research Institute, San Francisco, California, USA (I. Steffen, K. Lu, L.K. Yamamoto, G. Simmons); University of California, San Francisco (I. Steffen, K. Lu, G. Simmons); University of California, Los Angeles, California, USA (N.A. Hoff, A.W. Rimoin); University of Kinshasa, Kinshasa, Democratic Republic of the Congo (P. Mulembakani, E.O. Wemakoy); Institut National de Recherche Biomedicale, Kinshasa (J.-J. Muyembe-Tamfum); Institute of Human Virology, Abuja, Nigeria (N. Ndembi); Abbott Diagnostics, Abbott Park, Illinois, USA (C.A. Brennan, J. Hackett Jr.); American Red Cross Scientific Support Office, Gaithersburg, Maryland, USA (S.L. Stramer); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.M. Switzer); Institut National de la Santé et de la Recherche Médicale Unité 941, Paris, France (S. Saragosti); Centre National de Transfusion Sanguine, Kinshasa (G.O. Mbensa); Institut National de la Transfusion Sanguine, Paris (S. Laperche)

Main Article

Assay results for study of serologic prevalence of Ebola virus in equatorial Africa*

Country	City	Risk group	Collection period	No. samples	No. (%) EBOV neut+	No. (%) EBOV LIPS+	No. (%) EBOV ELISA+/no. tested	No. (%) EBOV confirmed	95% CI, %†
Uganda	Unknown	AIDS	1997	106	0	1 (0.9)	0/1	0	0–1 (0–0.9)
Cameroon	Unknown	AIDS	1997	96	0	4 (4.2)	0/4	0	0–4 (0–4.2)
Ghana	Unknown	AIDS	1997	48	0	0	0/0	0	0
Cameroon	All locations	Illness of unknown etiology	2011–2012	160	2 (1.3)	4 (2.5)	2/6 (33.3)	2 (1.3)	0–6 (0–3.8)
Cameroon	Djoum	Illness of unknown etiology	2011–2012	35	0	1 (2.9)	0/1	0	0–1 (0–2.9)
Cameroon	Ebolowa	Illness of unknown etiology	2011–2012	80	0	1 (1.3)	0/1	0	0–1 (0–1.3)
Cameroon	Sangmelima	lllness of unknown etiology	2011–2012	45	2 (4.4)	2 (4.4)	2/4 (50.0)	2 (4.4)	2–4 (4.4–8.9)
ROC	All locations	HIV surveillance	1999	458	4 (0.9)	9 (2.0)	9/13 (69.2)	9 (2.0)	0–13 (0–2.8)
ROC	Madingou	HIV surveillance	1999	149	1 (0.7)	1 (0.7)	1/2 (50.0)	1 (0.7)	0–2 (0–1.3)
ROC	Nkayi	HIV surveillance	1999	149	0	3 (2.0)	3/3 (100.0)	3 (2.0)	0–3 (0–2.0)
ROC	Owando	HIV surveillance	1999	160	3 (1.9)	5 (3.1)	5/8 (62.5)	5 (3.1)	0–8 (0–5.0)
DRC	Kinshasa	Blood donors	2011–2012	752	12 (1.6)	38 (5.1)	8/38 (21.1)	15 (2.0)	5–38 (0.7–5.1)
DRC	Kasaï Oriental	Monkeypox surveillance	2007	810	15 (1.9)	52 (6.4)	15/54 (27.8)	27 (3.3)	1–54 (0.1–6.7)
Total	NA	NA	1997–2012	2,430	33 (1.4)	108 (4.4)	34/116 (29.3)	53 (2.2)	6–116 (0.3–4.8)

*Confirmed seroprevalence rates are based on reactivity in >2 different assay formats. DRC, Democratic Republic of the Congo; EBOV, Ebola virus; LIPS, luciferase immunoprecipitation system; NA, not applicable; neut, neutralization assay; ROC, Republic of the Congo; +, positive.
†Based on number of samples reactive in all 3 assays to number of samples reactive in a single assay (values in parentheses).

Main Article

¹Current affiliation: University of Veterinary Medicine, Hannover, Germany.

Page created: April 17, 2019

Page updated: April 17, 2019

Page reviewed: April 17, 2019

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.